Angiotensin II has been studied for many years and has consistently shown to increase MAP. This medication adds a new mechanism of action to the vasopressor arsenal that is already used for septic shock. Angiotensin II should be reserved for patients in septic shock who do not respond to high doses of catecholamines and vasopressin. The only drug interactions with angiotensin II known to date are with concomitant use of ACE inhibitors, which can increase the response to angiotensin II and angiotensin II receptor blockers (ARBs), which may decrease the response to angiotensin II. The 2016 Surviving Sepsis Campaign (SSC) International Guidelines for Management of Sepsis and Septic Shock recommend immediate hemodynamic support to combat the rapid decline in tissue perfusion that is an inherent complication of sepsis and septic shock.

Read More